United States Biotechnology & Medical Research

Enliven Therapeutics, Inc. (ELVN)

Track

Track

Enliven Therapeutics experienced seventeen transactions d'initiés over ninety days, totaling over six hundred thousand dollars in net selling. Directors and officers executed these planned divestments following a recent earnings report miss. Despite a twenty-six percent stock decline, leadership activity remains focused on liquidating holdings rather than acquiring new equity positions.
Ticker: ELVN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Enliven Therapeutics, Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
46.35
Quantity 19,345 +25.6%
Value US$4,650,114
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
64.69
Quantity 31,742 +29.5%
Value US$2,418,159
Collins Helen Louise Director Non-Executive Director
Transaction date
Proposed sale
Price
26.06
Quantity 45,641
Value US$636,565
Garland J. Scott Non-Executive Director
Transaction date
Sale
Price
46.67
Quantity 13,000 -100.0%
Value US$606,719
JEFFREY GARLAND Director Non-Executive Director
Transaction date
Proposed sale
Price
46.67
Quantity 13,000
Value US$606,719
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
51.49
Quantity 289 -0.8%
Value US$14,881
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
50.72
Quantity 2,194 -5.4%
Value US$111,270
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
50.03
Quantity 3,535 -8.0%
Value US$176,851
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
51.48
Quantity 240 -1.0%
Value US$12,356
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
50.71
Quantity 1,844 -6.8%
Value US$93,507
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
50.03
Quantity 2,916 -9.7%
Value US$145,891
0.5
Hohl Benjamin Officer Officer
Transaction date
Proposed sale
Price
49.12
Quantity 12,036
Value US$591,208
Heyman Richard A. resigned from BOD
Transaction date
Proposed sale
Price
59.29
Quantity 38,000
Value US$2,252,830
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
59.35
Quantity 1,388 -3.4%
Value US$82,383
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
58.35
Quantity 4,630 -10.1%
Value US$270,168
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
59.35
Quantity 1,100 -4.2%
Value US$65,281
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
58.37
Quantity 3,900 -13.0%
Value US$227,650
Derynck Mika K Non-Executive Director
Transaction date
Planned sale
Price
60.21
Quantity 158,795 -100.0%
Value US$9,561,587
Derynck Mika K Director Non-Executive Director
Transaction date
Proposed sale
Price
58.04
Quantity 158,795
Value US$9,216,462
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
53.87
Quantity 123 -0.3%
Value US$6,626
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
53.38
Quantity 2,638 -5.4%
Value US$140,823
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
52.32
Quantity 2,564 -5.0%
Value US$134,143
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
51.48
Quantity 369 -0.7%
Value US$18,997
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
49.97
Quantity 324 -0.6%
Value US$16,191
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
53.92
Quantity 63 -0.3%
Value US$3,397
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
53.42
Quantity 2,184 -8.0%
Value US$116,669
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
52.39
Quantity 2,063 -7.0%
Value US$108,085
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
51.55
Quantity 459 -1.5%
Value US$23,660
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
50.05
Quantity 231 -0.8%
Value US$11,563
Collins Helen Louise Officer Officer
Transaction date
Proposed sale
Price
50.86
Quantity 15,000
Value US$762,900
Kunkel Lori Anne Non-Executive Director
Transaction date
Planned sale
Price
50.84
Quantity 5,889 -12.3%
Value US$299,421
Kunkel Lori Anne Non-Executive Director
Transaction date
Planned sale
Price
49.98
Quantity 4,111 -7.9%
Value US$205,482
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.00
Quantity 46,776 -0.7%
Value US$2,104,920
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.38
Quantity 787,024 -10.7%
Value US$35,715,149
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.00
Quantity 1,477 -0.7%
Value US$66,465
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.38
Quantity 24,846 -10.1%
Value US$1,127,511
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
44.75
Quantity 1,238 -2.4%
Value US$55,397
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
44.75
Quantity 1,238 -2.4%
Value US$55,397
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
43.86
Quantity 3,401 -6.1%
Value US$149,179
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
43.86
Quantity 3,401 -6.1%
Value US$149,179
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
42.79
Quantity 1,379 -2.4%
Value US$59,001
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
42.79
Quantity 1,379 -2.4%
Value US$59,001
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
44.74
Quantity 1,133 -4.3%
Value US$50,694
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
44.74
Quantity 1,133 -4.3%
Value US$50,694
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
43.87
Quantity 2,599 -9.0%
Value US$114,018
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
43.87
Quantity 2,599 -9.0%
Value US$114,018
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
42.83
Quantity 1,268 -4.2%
Value US$54,305
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
42.83
Quantity 1,268 -4.2%
Value US$54,305
0.5
Hohl Benjamin Officer Officer
Transaction date
Proposed sale
Price
42.55
Quantity 18,054
Value US$768,198
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.02
Quantity 272,322 -3.6%
Value US$12,259,936
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.02
Quantity 9,086 -3.6%
Value US$409,052
Kunkel Lori Anne Non-Executive Director
Transaction date
Planned sale
Price
35.82
Quantity 354 -0.7%
Value US$12,680
Kunkel Lori Anne Non-Executive Director
Transaction date
Planned sale
Price
35.36
Quantity 1,867 -3.5%
Value US$66,012
Kunkel Lori Anne Non-Executive Director
Transaction date
Planned sale
Price
34.28
Quantity 7,779 -12.6%
Value US$266,659
Kunkel Lori Anne Board Member
Transaction date
Proposed sale
Price
35.49
Quantity 20,000
Value US$709,800
Kunkel Lori Anne Board Member
Transaction date
Proposed sale
Price
35.49
Quantity 20,000
Value US$709,800
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
41.21
Quantity 223 -0.9%
Value US$9,189
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
40.25
Quantity 1,302 -4.9%
Value US$52,402
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
39.53
Quantity 3,475 -11.6%
Value US$137,381
Collins Helen Louise Officer Officer
Transaction date
Proposed sale
Price
41.34
Quantity 15,000
Value US$620,100
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-10-21 2026-10-19 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
19,345 +25.6%
46.35
US$4,650,114 		19,345 +25.6% 46.35 US$4,650,114
2026-10-21 2026-10-19 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
31,742 +29.5%
64.69
US$2,418,159 		31,742 +29.5% 64.69 US$2,418,159
2026-10-19 2026-10-19 PrS Proposed sale
Collins Helen Louise

Director

Non-Executive Director
45,641
26.06
US$636,565 		45,641 26.06 US$636,565
2026-10-05 2026-10-01 S Sale
Garland J. Scott
Non-Executive Director
13,000 -100.0%
46.67
US$606,719 		13,000 -100.0% 46.67 US$606,719
2026-10-01 2026-10-01 PrS Proposed sale
JEFFREY GARLAND

Director

Non-Executive Director
13,000
46.67
US$606,719 		13,000 46.67 US$606,719
2026-09-21 2026-09-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
289 -0.8%
51.49
US$14,881 		289 -0.8% 51.49 US$14,881
2026-09-21 2026-09-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
2,194 -5.4%
50.72
US$111,270 		2,194 -5.4% 50.72 US$111,270
2026-09-21 2026-09-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
3,535 -8.0%
50.03
US$176,851 		3,535 -8.0% 50.03 US$176,851
2026-09-21 2026-09-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
240 -1.0%
51.48
US$12,356 		240 -1.0% 51.48 US$12,356
2026-09-21 2026-09-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,844 -6.8%
50.71
US$93,507 		1,844 -6.8% 50.71 US$93,507
2026-09-21 2026-09-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
2,916 -9.7%
50.03
US$145,891 		2,916 -9.7% 50.03 US$145,891
2026-09-17 2026-09-17 PrS Proposed sale
0.5
Hohl Benjamin

Officer

Officer
12,036
49.12
US$591,208 		12,036 49.12 US$591,208
2026-09-04 2026-09-04 PrS Proposed sale
Heyman Richard A.

resigned from BOD
38,000
59.29
US$2,252,830 		38,000 59.29 US$2,252,830
2026-08-19 2026-08-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
1,388 -3.4%
59.35
US$82,383 		1,388 -3.4% 59.35 US$82,383
2026-08-19 2026-08-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
4,630 -10.1%
58.35
US$270,168 		4,630 -10.1% 58.35 US$270,168
2026-08-19 2026-08-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,100 -4.2%
59.35
US$65,281 		1,100 -4.2% 59.35 US$65,281
2026-08-19 2026-08-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
3,900 -13.0%
58.37
US$227,650 		3,900 -13.0% 58.37 US$227,650
2026-08-06 2026-08-04 PlS Planned sale
Derynck Mika K
Non-Executive Director
158,795 -100.0%
60.21
US$9,561,587 		158,795 -100.0% 60.21 US$9,561,587
2026-08-04 2026-08-04 PrS Proposed sale
Derynck Mika K

Director

Non-Executive Director
158,795
58.04
US$9,216,462 		158,795 58.04 US$9,216,462
2026-07-21 2026-07-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
123 -0.3%
53.87
US$6,626 		123 -0.3% 53.87 US$6,626
2026-07-21 2026-07-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
2,638 -5.4%
53.38
US$140,823 		2,638 -5.4% 53.38 US$140,823
2026-07-21 2026-07-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
2,564 -5.0%
52.32
US$134,143 		2,564 -5.0% 52.32 US$134,143
2026-07-21 2026-07-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
369 -0.7%
51.48
US$18,997 		369 -0.7% 51.48 US$18,997
2026-07-21 2026-07-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
324 -0.6%
49.97
US$16,191 		324 -0.6% 49.97 US$16,191
2026-07-21 2026-07-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
63 -0.3%
53.92
US$3,397 		63 -0.3% 53.92 US$3,397
2026-07-21 2026-07-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
2,184 -8.0%
53.42
US$116,669 		2,184 -8.0% 53.42 US$116,669
2026-07-21 2026-07-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
2,063 -7.0%
52.39
US$108,085 		2,063 -7.0% 52.39 US$108,085
2026-07-21 2026-07-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
459 -1.5%
51.55
US$23,660 		459 -1.5% 51.55 US$23,660
2026-07-21 2026-07-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
231 -0.8%
50.05
US$11,563 		231 -0.8% 50.05 US$11,563
2026-07-17 2026-07-17 PrS Proposed sale
Collins Helen Louise

Officer

Officer
15,000
50.86
US$762,900 		15,000 50.86 US$762,900
2026-07-08 2026-07-06 PlS Planned sale
Kunkel Lori Anne
Non-Executive Director
5,889 -12.3%
50.84
US$299,421 		5,889 -12.3% 50.84 US$299,421
2026-07-08 2026-07-06 PlS Planned sale
Kunkel Lori Anne
Non-Executive Director
4,111 -7.9%
49.98
US$205,482 		4,111 -7.9% 49.98 US$205,482
2026-06-24 2026-06-22 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
46,776 -0.7%
45.00
US$2,104,920 		46,776 -0.7% 45.00 US$2,104,920
2026-06-24 2026-06-22 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
787,024 -10.7%
45.38
US$35,715,149 		787,024 -10.7% 45.38 US$35,715,149
2026-06-24 2026-06-22 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
1,477 -0.7%
45.00
US$66,465 		1,477 -0.7% 45.00 US$66,465
2026-06-24 2026-06-22 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
24,846 -10.1%
45.38
US$1,127,511 		24,846 -10.1% 45.38 US$1,127,511
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
1,477
45.96
US$67,883 		1,477 45.96 US$67,883
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
1,477
45.96
US$67,883 		1,477 45.96 US$67,883
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
24,846
45.96
US$1,141,922 		24,846 45.96 US$1,141,922
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
24,846
45.96
US$1,141,922 		24,846 45.96 US$1,141,922
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
46,776
45.96
US$2,149,825 		46,776 45.96 US$2,149,825
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
46,776
45.96
US$2,149,825 		46,776 45.96 US$2,149,825
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
787,024
45.96
US$36,171,623 		787,024 45.96 US$36,171,623
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
787,024
45.96
US$36,171,623 		787,024 45.96 US$36,171,623
2026-06-22 2026-06-22 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
1,747
45.96
US$80,292 		1,747 45.96 US$80,292
2026-06-22 2026-06-22 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
1,747
45.96
US$80,292 		1,747 45.96 US$80,292
2026-06-22 2026-06-22 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
29,385
45.96
US$1,350,535 		29,385 45.96 US$1,350,535
2026-06-22 2026-06-22 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
29,385
45.96
US$1,350,535 		29,385 45.96 US$1,350,535
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
1,238 -2.4%
44.75
US$55,397 		1,238 -2.4% 44.75 US$55,397
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
1,238 -2.4%
44.75
US$55,397 		1,238 -2.4% 44.75 US$55,397
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
3,401 -6.1%
43.86
US$149,179 		3,401 -6.1% 43.86 US$149,179
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
3,401 -6.1%
43.86
US$149,179 		3,401 -6.1% 43.86 US$149,179
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
1,379 -2.4%
42.79
US$59,001 		1,379 -2.4% 42.79 US$59,001
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
1,379 -2.4%
42.79
US$59,001 		1,379 -2.4% 42.79 US$59,001
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,133 -4.3%
44.74
US$50,694 		1,133 -4.3% 44.74 US$50,694
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,133 -4.3%
44.74
US$50,694 		1,133 -4.3% 44.74 US$50,694
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
2,599 -9.0%
43.87
US$114,018 		2,599 -9.0% 43.87 US$114,018
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
2,599 -9.0%
43.87
US$114,018 		2,599 -9.0% 43.87 US$114,018
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,268 -4.2%
42.83
US$54,305 		1,268 -4.2% 42.83 US$54,305
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,268 -4.2%
42.83
US$54,305 		1,268 -4.2% 42.83 US$54,305
2026-06-17 2026-06-17 PrS Proposed sale
0.5
Hohl Benjamin

Officer

Officer
18,054
42.55
US$768,198 		18,054 42.55 US$768,198
2026-06-17 2026-06-15 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
272,322 -3.6%
45.02
US$12,259,936 		272,322 -3.6% 45.02 US$12,259,936
2026-06-17 2026-06-15 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
9,086 -3.6%
45.02
US$409,052 		9,086 -3.6% 45.02 US$409,052
2026-06-15 2026-06-15 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
10,243
42.36
US$433,893 		10,243 42.36 US$433,893
2026-06-15 2026-06-15 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
272,322
42.36
US$11,535,560 		272,322 42.36 US$11,535,560
2026-06-15 2026-06-15 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
9,086
42.36
US$384,883 		9,086 42.36 US$384,883
2026-06-09 2026-06-05 PlS Planned sale
Kunkel Lori Anne
Non-Executive Director
354 -0.7%
35.82
US$12,680 		354 -0.7% 35.82 US$12,680
2026-06-09 2026-06-05 PlS Planned sale
Kunkel Lori Anne
Non-Executive Director
1,867 -3.5%
35.36
US$66,012 		1,867 -3.5% 35.36 US$66,012
2026-06-09 2026-06-05 PlS Planned sale
Kunkel Lori Anne
Non-Executive Director
7,779 -12.6%
34.28
US$266,659 		7,779 -12.6% 34.28 US$266,659
2026-06-05 2026-06-05 PrS Proposed sale
Kunkel Lori Anne

Board Member
20,000
35.49
US$709,800 		20,000 35.49 US$709,800
2026-06-05 2026-06-05 PrS Proposed sale
Kunkel Lori Anne

Board Member
20,000
35.49
US$709,800 		20,000 35.49 US$709,800
2026-05-20 2026-05-18 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
223 -0.9%
41.21
US$9,189 		223 -0.9% 41.21 US$9,189
2026-05-20 2026-05-18 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,302 -4.9%
40.25
US$52,402 		1,302 -4.9% 40.25 US$52,402
2026-05-20 2026-05-18 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
3,475 -11.6%
39.53
US$137,381 		3,475 -11.6% 39.53 US$137,381
2026-05-18 2026-05-18 PrS Proposed sale
Collins Helen Louise

Officer

Officer
15,000
41.34
US$620,100 		15,000 41.34 US$620,100
Explore more

More insider trading research around Enliven Therapeutics, Inc.

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America